Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | IAPP | P10997 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL10992898 | 0.97 | L3MBTL1 (0.60) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL7150622 | 0.93 | L3MBTL1 (0.52) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL80263 | 0.91 | L3MBTL1 (0.50) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL3687049 | 0.91 | AKR1B1 (0.61) | L3MBTL1AKR1B1ALDH1A1LMNAMAPT | |
| SCHEMBL29676820 | 0.91 | AKR1B1 (0.61) | L3MBTL1AKR1B1ALDH1A1LMNAMAPT | |
| SCHEMBL11283717 | 0.89 | L3MBTL1 (0.49) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL27734152 | 0.89 | L3MBTL1 (0.53) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL13369550 | 0.89 | L3MBTL1 (0.49) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL8109115 | 0.89 | L3MBTL1 (0.49) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA | |
| SCHEMBL21100153 | 0.87 | L3MBTL1 (0.47) | L3MBTL1AKR1B1CYP3A4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-108109963-B | Display unit, method of manufacturing the same, and electronic apparatus | 索尼公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-104425624-B | Electronic device, image display device and the substrate for constituting image display device | 索尼公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-108109963-A | Display unit and its manufacturing method and electronic equipment | 索尼公司 | 2018-06-01 | — | — | CN | disclosed |
| WO-2017205309-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| CN-106952929-A | Display unit and its manufacture method and electronic equipment | 索尼公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-103972263-A | Display unit, method of manufacturing the same, and electronic apparatus | SONY CORP | 2014-08-06 | — | — | CN | disclosed |
| US-6833373-B1 | N-(3-hydroxy-5-((1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl) -amino)-benzoyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine and tamoxifen; breast cancer | G.D. SEARLE & CO. | 2004-12-21 | — | — | US | disclosed |
| US-4463171-A | BACTERICIDES | SANRAKU-OCEAN CO., LTD. (JP) | 1984-07-31 | — | — | US | disclosed |
| EP-0017970-B1 | NOVEL BETA-LACTAM DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | SANRAKU-OCEAN CO., LTD. (JP) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | L3MBTL1 3712/4885AKR1B1 1392/4885CYP3A4 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.